产品
编 号：F624089
分子式：C22H25F8N5O8
分子量：639.45
分子式：C22H25F8N5O8
分子量：639.45
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1374639-74-3
产品详情
生物活性：
Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications.
体内研究：
Gemigliptin tartrate (100 mg/kg; i.g.; daily; for 12 weeks) inhibits AGEs formation and AGE cross-links in vivo.Gemigliptin tartrate dose-dependently inhibits plasma DPP-4 activity in rats, dogs, and monkeys.Animal Model:Male C57BL/KsJ-db/db mice (7 weeks old)
Dosage:100 mg/kg
Administration:Oral gavage, daily, for 12 weeks
Result:Significantly reduced circulating AGE levels by 44.5% in serum.
体外研究：
Gemigliptin tartrate dose-dependently inhibits the formation of AGE-BSA with IC50 of 11.69 mM.Gemigliptin tartrate dose-dependently suppresses the cross-linking of preformed AGE-BSA with rat tail tendon collagen with an IC50 of 1.39 mM.Gemigliptin tartrate is a competitive DPP-4 inhibitor with a Ki of 7.25 nM.
Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications.
体内研究：
Gemigliptin tartrate (100 mg/kg; i.g.; daily; for 12 weeks) inhibits AGEs formation and AGE cross-links in vivo.Gemigliptin tartrate dose-dependently inhibits plasma DPP-4 activity in rats, dogs, and monkeys.Animal Model:Male C57BL/KsJ-db/db mice (7 weeks old)
Dosage:100 mg/kg
Administration:Oral gavage, daily, for 12 weeks
Result:Significantly reduced circulating AGE levels by 44.5% in serum.
体外研究：
Gemigliptin tartrate dose-dependently inhibits the formation of AGE-BSA with IC50 of 11.69 mM.Gemigliptin tartrate dose-dependently suppresses the cross-linking of preformed AGE-BSA with rat tail tendon collagen with an IC50 of 1.39 mM.Gemigliptin tartrate is a competitive DPP-4 inhibitor with a Ki of 7.25 nM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备